Project Grant HT94252410025
Award Date
4/1/24
Completion Date
3/31/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
This federal Project Grant award, valued at $161,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "BREAST CANCER BRAIN METASTASES: INTEGRATING IMMUNOGENOMIC AND PHENOTYPIC VULNERABILITIES TO IMPROVE OUTCOMES", will support advanced biomedical research focused on transforming healthcare for military service members and the broader public. The award, with a performance period from April 1, 2025 to...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $724,500.00 to Duke University to conduct research targeted at eliminating residual breast cancer. The research aims to investigate dormancy-associated immune tolerance as a strategy to treat breast cancer. The award has a performance period from Mar 1, 2025 to Feb 29, 2028. This grant supports Duke University's ongoing efforts to advance innovative medical...
The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
This federal Project Grant award in the amount of $4,503,963 was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports a research project titled "Spatial Reprogramming of Tumor Immune Microenvironments by Preoperative Radiotherapy and Immune Checkpoint Inhibition in HER2 Negative Breast Cancer." The project is being led by the University of North Carolina at Chapel Hill (UNC-CH) through its Office of Sponsored...
The University of Massachusetts Amherst was awarded a $557,247 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from February 1, 2023 to January 31, 2026 to develop intracellular bacterial delivery of vaccine antigens to establish T-cell antitumor immunity in triple-negative breast cancer. The Military Medical Research and Development program supports innovative medical research with...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,301,250.00 to Health Research, Inc. to conduct research aimed at "Inhibiting MDSC Biogenesis to Augment Immunotherapy Efficacy in Triple-Negative Breast Cancer". The 3-year award, beginning on March 1, 2025 and ending on February 29, 2028, will support advanced biomedical research to transform healthcare for military service members and the...
The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...